Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Recursion Pharmaceuticals ( (RXRX) ) is now available.
On October 29, 2025, Recursion Pharmaceuticals announced that Roche exercised its option for the Microglia Map, a pioneering whole genome map of brain immune cells, under their collaboration agreement. As a result, Roche will pay Recursion an Acceptance Fee of $30 million, highlighting the significant impact of this collaboration on Recursion’s operations and industry positioning.
The most recent analyst rating on (RXRX) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Recursion Pharmaceuticals stock, see the RXRX Stock Forecast page.
Spark’s Take on RXRX Stock
According to Spark, TipRanks’ AI Analyst, RXRX is a Neutral.
Recursion Pharmaceuticals’ overall stock score is primarily influenced by its financial performance challenges, including negative profit margins and cash flow issues. Despite these challenges, the company shows strong technical momentum and promising technological advancements, as highlighted in the earnings call. However, valuation concerns and reliance on partnerships for revenue remain significant risks.
To see Spark’s full report on RXRX stock, click here.
More about Recursion Pharmaceuticals
Recursion Pharmaceuticals, Inc. operates in the biotechnology industry, focusing on developing innovative solutions involving whole genome mapping and collaboration with major pharmaceutical companies.
Average Trading Volume: 37,587,064
Technical Sentiment Signal: Buy
Current Market Cap: $2.57B
For detailed information about RXRX stock, go to TipRanks’ Stock Analysis page.